|
CN112226381A
|
|
Beef pancreatin digestive juice and preparation method thereof
|
|
CN111690059A
|
|
Monoclonal antibody 1D7 for resisting SARS-CoV-2
|
|
CN111732654A
|
|
Monoclonal antibody 1E10 for resisting SARS-CoV-2
|
|
CN111718411A
|
|
Monoclonal antibody 1F2 for resisting SARS-CoV-2
|
|
CN111569058A
|
|
SARS-CoV-2 inactivated vaccine and its preparation method
|
|
CN111733096A
|
|
Gaojinger digestive juice and preparation method thereof
|
|
CN111249456A
|
|
Purification method of rabies virus inactivated vaccine
|
|
CN111411086A
|
|
Coxsackie group A5 virus strain capable of effectively infecting old young mice
|
|
CN110845610A
|
|
Detection antibody pair aiming at diphtheria toxoid and application thereof
|
|
CN110845609A
|
|
Detection antibody pair aiming at tetanus toxoid and application thereof
|
|
CN110527659A
|
|
For producing the suspension cell strain of influenza vaccines
|
|
CN110184242A
|
|
The mouse strong virus force of 6 type of Coxsackie virus A group (CVA6) attacks strain and its application
|
|
CN109234241A
|
|
A kind of Coxsackie virus CVA16 type velogen strain CVA16-B6-714 and its application
|
|
CN108508197A
|
|
A kind of human von willebrand disease factor（vWF）Active immue quantitative detection reagent box
|
|
CN108277199A
|
|
Wide spectrum low oncogenicity mdck cell system and its application
|
|
CN108570098A
|
|
A kind of isolation and purification method of a variety of antigenic components of pertussis
|
|
CN108103002A
|
|
Preparation of mdck cell host's residual protein and application thereof
|
|
CN107603942A
|
|
Mdck cell strain for influenza vaccines production
|
|
CN106008706A
|
|
Virus inactivation method for human alpha1-antitrypsin product
|
|
CN106167797A
|
|
Human fibrin dissolves lyophilized formulations of proenzyme and preparation method thereof
|
